866-997-4948(US-Canada Toll Free)

Medulloblastoma - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Oncology

No. of Pages : 49 Pages


Global Markets Directs, \'Medulloblastoma Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Medulloblastoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Medulloblastoma. 

Medulloblastoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Medulloblastoma.
  • A review of the Medulloblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Medulloblastoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Medulloblastoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Medulloblastoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Medulloblastoma Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Medulloblastoma 7
Medulloblastoma Therapeutics under Development by Companies 9
Medulloblastoma Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Discovery and Pre-Clinical Stage Products 14
Comparative Analysis 14
Medulloblastoma Therapeutics - Products under Development by Companies 15
Medulloblastoma Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Medulloblastoma Therapeutics Development 17
Eli Lilly and Company 17
Novartis AG 18
Lixte Biotechnology Holdings, Inc. 19
Stemline Therapeutics, Inc. 20
Archer Biosciences, Inc 21
Medulloblastoma - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
SL-301 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
CST-102 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
erismodegib - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
erismodegib - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
vismodegib - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
vismodegib - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ARC-100 + [temozolomide] - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
LY-2940680 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
siomycin A - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
carboplatin + vincristine sulfate + Radiation Therapy - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
LB-102 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Medulloblastoma Therapeutics - Drug Profile Updates 42
Medulloblastoma Therapeutics - Dormant Products 45
Medulloblastoma - Product Development Milestones 46
Featured News & Press Releases 46
Sep 19, 2011: Researchers Discover Regulatory Protein As Potential Drug Target For Brain Tumors 46

Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49

List of Table


Number of Products Under Development for Medulloblastoma, H1 2013 7
Products under Development for Medulloblastoma - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Early Clinical Stage Development, H1 2013 13
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 14
Products under Development by Companies, H1 2013 15
Products under Investigation by Universities/Institutes, H1 2013 16
Eli Lilly and Company, H1 2013 17
Novartis AG, H1 2013 18
Lixte Biotechnology Holdings, Inc., H1 2013 19
Stemline Therapeutics, Inc., H1 2013 20
Archer Biosciences, Inc, H1 2013 21
Assessment by Monotherapy Products, H1 2013 22
Assessment by Combination Products, H1 2013 23
Assessment by Stage and Route of Administration, H1 2013 25
Assessment by Stage and Molecule Type, H1 2013 27
Medulloblastoma Therapeutics - Drug Profile Updates 42
Medulloblastoma Therapeutics - Dormant Products 45

List of Chart


Number of Products under Development for Medulloblastoma, H1 2013 7
Products under Development for Medulloblastoma - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Early Clinical Stage Products, H1 2013 13
Discovery and Pre-Clinical Stage Products, H1 2013 14
Assessment by Monotherapy Products, H1 2013 22
Assessment by Combination Products, H1 2013 23
Assessment by Route of Administration, H1 2013 24
Assessment by Stage and Route of Administration, H1 2013 25
Assessment by Molecule Type, H1 2013 26
Assessment by Stage and Molecule Type, H1 2013 27

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *